Prognosis in patients with synchronous colorectal cancer metastases after complete resection of the primary tumor and the metastases

被引:25
作者
Stelzner, Sigmar [1 ]
Radulova-Mauersberger, Olga [1 ]
Zschuppe, Ernst [2 ]
Kittner, Thomas [3 ]
Abolmaali, Nasreddin [3 ]
Puffer, Eric [4 ]
Zimmer, Joerg [5 ]
Witzigmann, Helmut [1 ]
机构
[1] Tech Univ Dresden, Teaching Hosp, Stadt Klinikum Dresden, Dept Gen & Visceral Surg, Dresden, Germany
[2] Tech Univ Dresden, Teaching Hosp, Stadt Klinikum Dresden, Dept Med Oncol, Dresden, Germany
[3] Tech Univ Dresden, Teaching Hosp, Stadt Klinikum Dresden, Dept Radiol, Dresden, Germany
[4] Tech Univ Dresden, Teaching Hosp, Stadt Klinikum Dresden, Dept Pathol, Dresden, Germany
[5] Tech Univ Dresden, Teaching Hosp, Stadt Klinikum Dresden, Dept Radiat Therapy, Dresden, Germany
关键词
multidisciplinary team; overall survival; primary tumor resection; resectable metastases; synchronous colorectal cancer metastases; LIVER METASTASES; HEPATIC RESECTION; PERITONEAL CARCINOMATOSIS; NEOADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL; PLUS IRINOTECAN; SURVIVAL; MANAGEMENT; SURGERY; FLUOROURACIL;
D O I
10.1002/jso.25578
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Synchronous metastases are considered a negative prognostic factor in patients with metastatic colorectal cancer (CRC). We investigated the outcomes of stage IV CRC patients undergoing complete gross resection (R0/1) of both the primary tumor and the metastases under the guidance of a multidisciplinary team (MDT). Methods All CRC patients with synchronous metastases were retrieved from a prospective database. Patients treated from 2006 to 2017 who underwent complete resection were analyzed. Various factors, including multiple metastatic sites and complex procedures, were investigated. Univariate and multivariate overall survival (OS) calculations were performed. Results Of 330 consecutive patients with synchronous metastases, 101 (30.6%) achieved an R0/1 status including 12 (11.9%) patients with multiple metastatic sites. Complex procedures were necessary in 45 (44.6%) patients. Five-year OS was 53.0% for the R0/1 patient group. Multivariate analysis could not detect factors associated with prognosis. Conclusions With modern treatment, the prognosis of patients with synchronous CRC metastases can be improved. Decisions made by a MDT offered one-third of patients a potentially curative approach to their stage IV disease. Despite the treatment of a high rate of patients with complex metastases necessitating complex procedures, we achieved a favorable 5-year OS rate.
引用
收藏
页码:438 / 445
页数:8
相关论文
共 42 条
[1]  
Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
[2]   Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus [J].
Adam, Rene ;
de Gramont, Aimery ;
Figueras, Joan ;
Kokudo, Norihiro ;
Kunstlinger, Francis ;
Loyer, Evelyne ;
Poston, Graeme ;
Rougier, Philippe ;
Rubbia-Brandt, Laura ;
Sobrero, Alberto ;
Teh, Catherine ;
Tejpar, Sabine ;
Van Cutsem, Eric ;
Vauthey, Jean-Nicolas ;
Pahlman, Lars .
CANCER TREATMENT REVIEWS, 2015, 41 (09) :729-741
[3]   Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases [J].
Andres, A. ;
Mentha, G. ;
Adam, R. ;
Gerstel, E. ;
Skipenko, O. G. ;
Barroso, E. ;
Lopez-Ben, S. ;
Hubert, C. ;
Majno, P. E. ;
Toso, C. .
BRITISH JOURNAL OF SURGERY, 2015, 102 (06) :691-699
[4]   Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy [J].
Bismuth, H ;
Adam, R ;
Levi, F ;
Farabos, C ;
Waechter, F ;
Castaing, D ;
Majno, P ;
Engerran, L .
ANNALS OF SURGERY, 1996, 224 (04) :509-520
[5]   SURGERY FOR SYNCHRONOUS HEPATIC METASTASES OF COLORECTAL-CANCER [J].
BISMUTH, H ;
CASTAING, D ;
TRAYNOR, O .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1988, 23 :144-149
[6]   Surgical Strategies for Synchronous Colorectal Liver Metastases in 156 Consecutive Patients: Classic, Combined or Reverse Strategy? [J].
Brouquet, Antoine ;
Mortenson, Melinda M. ;
Vauthey, Jean-Nicolas ;
Rodriguez-Bigas, Miguel A. ;
Overman, Michael J. ;
Chang, George J. ;
Kopetz, Scott ;
Garrett, Christopher ;
Curley, Steven A. ;
Abdalla, Eddie K. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2010, 210 (06) :934-941
[7]   Second-look surgery plus HIPEC for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Should we resect the initial anastomosis? An observational study [J].
Cloutier, A. S. ;
Faron, M. ;
Honore, C. ;
Goere, D. ;
Dumont, E. ;
Vittadello, F. ;
Elias, D. .
EJSO, 2015, 41 (08) :1068-1073
[8]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[9]   The role of image-guided therapy in the management of colorectal cancer metastatic disease [J].
de Baere, Thierry ;
Tselikas, Lambros ;
Yevich, Steven ;
Boige, Valerie ;
Deschamps, Frederic ;
Ducreux, Michel ;
Goere, Diane ;
Nguyen, France ;
Malka, David .
EUROPEAN JOURNAL OF CANCER, 2017, 75 :231-242
[10]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947